Health Economics›Non-small cell lung cancer›Advanced or metastatic disease first-line elderly or poor performance status

Advanced or metastatic disease first-line elderly or poor performance status

Non-small cell lung cancer · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	20.2 mo	—	—	2
Pemetrexed and Bevacizumab Variant #01	—	R 29 336	21d	—	~23.3 mo	—	—	1
Carboplatin, Pemetrexed, Bevacizumab Variant #01	—	R 16 050	21d	~6.8 mo	~12.6 mo	~10	~R 160 498 PFS proxy · indirect	2
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	6.0 mo	10.4 mo	4	R 61 352 PFS proxy	14
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	—	6.2 mo	—	—	4
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	5.3 mo	10.3 mo	8	R 40 246 PFS proxy	32
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 3 663	21d	6.0 mo	10.0 mo	9	R 32 967 PFS proxy	7
Gemcitabine and Vinorelbine Variant #01	—	R 3 329	21d	—	6.7 mo	—	—	2
Vinorelbine monotherapy Variant #01	—	R 583	21d	—	6.2 mo	—	—	3
Gemcitabine and Paclitaxel N/A - secondary systemic drug	—	R 263	28d	—	9.8 mo	—	—	1
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	—	8.4 mo	—	—	2
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	—	5.3 mo	—	—	1
Carboplatin and Pemetrexed N/A - secondary systemic drug	—	R 52	21d	8.6 mo	13.3 mo	13	R 677 PFS proxy	6

13 of 13 regimens shown